The latest marketing trends and market sales of Pralsetinib in 2025

Pralsetinib is a highly selective RETkinase inhibitor, mainly used to treat RETGene fusion or mutation-related non-small cell lung cancer (NSCLC), papillary thyroid carcinoma, and other RET driven solid tumors. In 2025, platinib will be officially launched in China, marking the further improvement of the domestic RET targeted therapy field and providing new treatment options for relevant patients. However, this drug has not yet been included in the domestic medical insurance system, so patients need to bear high out-of-pocket costs when purchasing and using it.

In the domestic market, Platinib is available in two common specifications: 100 mg 60 tablets and 100 mg 120 tablets. The price of a box is usually more than 20,000 yuan, and even as high as 60,000 yuan in some areas. Since the drug is an innovative targeted drug, its high price imposes a greater financial burden on patients, so detailed treatment evaluation and cost planning are required before use. At the same time, doctors will also formulate individualized dosage plans based on the patient's specific condition, weight, and concomitant medications.

Platinib is more expensive in overseas markets. The price of a box of 60 tablets of the original drug usually fluctuates between 40,000 and 100,000 yuan. Despite this, some patients still choose to obtain drugs through overseas channels to meet their treatment needs. In recent years, generic drugs of platinib have been developed overseas. The ingredients are basically the same as the original drug, and the price is obviously affordable. For example, the price of 120 generic drugs produced in Laos is about more than 3,000 yuan, providing patients with an affordable alternative while maintaining the clinical efficacy of the drug.

Overall, the launch and marketing of platinib in2025 will further enrich the targeted treatment options for RET gene-related tumors. Although domestic patients face high drug costs, they can purchase them through regular medical institutions and use them in a standardized manner in conjunction with clinicians’ treatment plans. For patients who purchase drugs overseas, they can choose lower-priced generic drugs. At the same time, they need to pay attention to the formality and safety of the source of the drugs to ensure the therapeutic effect and drug safety.

Reference link:https://www.drugs.com